Clorox (NYSE:CLX)‘s stock had its “hold” rating reiterated by Jefferies Group in a report released on Thursday. They currently have a $148.00 target price on the stock. Jefferies Group’s price target points to a potential upside of 1.59% from the stock’s current price.

A number of other research analysts have also weighed in on CLX. Wells Fargo & Co raised their price objective on Clorox from $130.00 to $146.00 and gave the company a “market perform” rating in a report on Thursday. Bank of America upgraded Clorox from an “underperform” rating to a “neutral” rating and set a $155.00 price objective on the stock in a report on Thursday. Zacks Investment Research lowered Clorox from a “hold” rating to a “sell” rating in a report on Wednesday, October 4th. BMO Capital Markets restated a “buy” rating and issued a $150.00 price objective on shares of Clorox in a report on Thursday, October 5th. Finally, Consumer Edge upgraded Clorox from a “neutral” rating to an “outperform” rating in a report on Friday, November 10th. Two investment analysts have rated the stock with a sell rating, eleven have issued a hold rating and three have issued a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $133.33.

Shares of Clorox (NYSE CLX) traded up $2.26 during trading hours on Thursday, hitting $145.69. The stock had a trading volume of 766,882 shares, compared to its average volume of 950,650. Clorox has a 52-week low of $118.41 and a 52-week high of $150.40. The stock has a market cap of $18,790.00, a price-to-earnings ratio of 26.73, a price-to-earnings-growth ratio of 3.94 and a beta of 0.42. The company has a quick ratio of 0.77, a current ratio of 1.10 and a debt-to-equity ratio of 3.02.

Clorox (NYSE:CLX) last announced its earnings results on Wednesday, November 1st. The company reported $1.46 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.41 by $0.05. The firm had revenue of $1.50 billion for the quarter, compared to analyst estimates of $1.48 billion. Clorox had a return on equity of 161.59% and a net margin of 11.84%. The business’s revenue was up 4.0% on a year-over-year basis. During the same quarter last year, the firm posted $1.36 EPS. analysts forecast that Clorox will post 5.6 earnings per share for the current year.

In other Clorox news, SVP Michael R. Costello sold 10,574 shares of the firm’s stock in a transaction on Tuesday, November 28th. The stock was sold at an average price of $136.01, for a total value of $1,438,169.74. Following the completion of the sale, the senior vice president now directly owns 34,867 shares of the company’s stock, valued at approximately $4,742,260.67. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Matthew T. Laszlo sold 20,051 shares of the firm’s stock in a transaction dated Wednesday, November 8th. The stock was sold at an average price of $130.46, for a total value of $2,615,853.46. Following the sale, the senior vice president now directly owns 10,896 shares of the company’s stock, valued at $1,421,492.16. The disclosure for this sale can be found here. 1.00% of the stock is owned by company insiders.

Large investors have recently modified their holdings of the stock. Sun Life Financial INC increased its position in shares of Clorox by 10,344.4% during the 2nd quarter. Sun Life Financial INC now owns 940 shares of the company’s stock worth $125,000 after purchasing an additional 931 shares during the last quarter. Acrospire Investment Management LLC acquired a new stake in shares of Clorox during the 2nd quarter worth about $133,000. Salem Investment Counselors Inc. increased its position in shares of Clorox by 2.5% during the 2nd quarter. Salem Investment Counselors Inc. now owns 1,256 shares of the company’s stock worth $167,000 after purchasing an additional 31 shares during the last quarter. Phocas Financial Corp. acquired a new stake in shares of Clorox during the 2nd quarter worth about $167,000. Finally, Jacobi Capital Management LLC increased its position in shares of Clorox by 0.3% during the 2nd quarter. Jacobi Capital Management LLC now owns 1,286 shares of the company’s stock worth $172,000 after purchasing an additional 4 shares during the last quarter. 73.14% of the stock is owned by hedge funds and other institutional investors.

WARNING: “Clorox’s (CLX) “Hold” Rating Reaffirmed at Jefferies Group” was first reported by American Banking News and is the property of of American Banking News. If you are accessing this news story on another publication, it was illegally copied and republished in violation of U.S. and international trademark & copyright laws. The original version of this news story can be read at https://www.americanbankingnews.com/2018/01/04/cloroxs-clx-hold-rating-reaffirmed-at-jefferies-group.html.

Clorox Company Profile

The Clorox Company is a manufacturer and marketer of consumer and professional products. The Company sells its products primarily through mass retail outlets, e-commerce channels, wholesale distributors and medical supply distributors. The Company operates through four segments: Cleaning, Household, Lifestyle and International.

Analyst Recommendations for Clorox (NYSE:CLX)

Receive News & Ratings for Clorox Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clorox and related companies with MarketBeat.com's FREE daily email newsletter.